CN104271227B - 赖氨酸‑谷氨酸二肽衍生物 - Google Patents
赖氨酸‑谷氨酸二肽衍生物 Download PDFInfo
- Publication number
- CN104271227B CN104271227B CN201380024470.5A CN201380024470A CN104271227B CN 104271227 B CN104271227 B CN 104271227B CN 201380024470 A CN201380024470 A CN 201380024470A CN 104271227 B CN104271227 B CN 104271227B
- Authority
- CN
- China
- Prior art keywords
- tert
- formula
- fluoren
- compound
- butoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(NC(CCC(NCCCCC(C(O*)=O)N*)=O)C(O*)=O)=O Chemical compound *C(NC(CCC(NCCCCC(C(O*)=O)N*)=O)C(O*)=O)=O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168119.1A EP2664374A1 (en) | 2012-05-15 | 2012-05-15 | Lysin-glutamic acid dipeptide derivatives |
| EP12168119.1 | 2012-05-15 | ||
| PCT/EP2013/059759 WO2013171135A1 (en) | 2012-05-15 | 2013-05-13 | Lysin-glutamic acid dipeptide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104271227A CN104271227A (zh) | 2015-01-07 |
| CN104271227B true CN104271227B (zh) | 2016-12-28 |
Family
ID=48430764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380024470.5A Active CN104271227B (zh) | 2012-05-15 | 2013-05-13 | 赖氨酸‑谷氨酸二肽衍生物 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9522874B2 (enExample) |
| EP (3) | EP2664374A1 (enExample) |
| JP (1) | JP6162795B2 (enExample) |
| KR (2) | KR102094928B1 (enExample) |
| CN (1) | CN104271227B (enExample) |
| AR (1) | AR091044A1 (enExample) |
| AU (1) | AU2013261894B2 (enExample) |
| BR (1) | BR112014028334B1 (enExample) |
| CA (2) | CA3096624C (enExample) |
| ES (2) | ES2692364T3 (enExample) |
| HR (2) | HRP20171058T1 (enExample) |
| IL (1) | IL235425B (enExample) |
| MX (2) | MX363728B (enExample) |
| MY (2) | MY184184A (enExample) |
| NZ (1) | NZ631215A (enExample) |
| PL (2) | PL3127604T3 (enExample) |
| RU (1) | RU2640812C2 (enExample) |
| SG (1) | SG11201406888QA (enExample) |
| SI (2) | SI3127604T1 (enExample) |
| WO (1) | WO2013171135A1 (enExample) |
| ZA (1) | ZA201407528B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| GB201315335D0 (en) * | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| JP6991196B2 (ja) | 2016-03-23 | 2022-02-03 | バッヘン・ホールディング・アクチエンゲゼルシャフト | グルカゴン様ペプチドを製造するための方法 |
| WO2020208409A1 (en) * | 2019-04-10 | 2020-10-15 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of peptide intermediates/modifiers |
| CN111454180A (zh) * | 2020-04-10 | 2020-07-28 | 大连阿拉宁生物技术有限公司 | 一种索马鲁肽侧链中间体及其制备方法 |
| CN113004370B (zh) * | 2021-02-09 | 2022-06-17 | 宁波绿之健药业有限公司 | 一种具有缓解高尿酸血症和调节肠道菌群的二肽及其应用 |
| EP4345104B1 (en) | 2022-09-30 | 2024-08-28 | Bachem Holding AG | Method for preparing liraglutide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006233405A (ja) * | 2005-08-16 | 2006-09-07 | Asahi Kasei Chemicals Corp | 繊維処理剤 |
| CN101993395A (zh) * | 2009-08-11 | 2011-03-30 | 住友化学株式会社 | 化合物和含有该化合物的光致抗蚀剂组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2283025T3 (es) * | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| ES2253353T3 (es) * | 2000-03-08 | 2006-06-01 | Novo Nordisk A/S | Reduccion del colesterol serico. |
| US20060258580A1 (en) * | 2003-05-14 | 2006-11-16 | Regents Of The University Of Michigan | Modulators of Nod1 signaling |
| IE20060841A1 (en) * | 2006-11-21 | 2008-05-28 | Ipsen Mfg Ireland Ltd | Boc and fmoc solid phase peptide synthesis |
| JP2008290987A (ja) * | 2007-05-28 | 2008-12-04 | Shiseido Co Ltd | Ｃｍｃ修復剤、毛髪化粧料およびｃｍｃ修復方法 |
| JP5127316B2 (ja) * | 2007-06-22 | 2013-01-23 | 旭化成ケミカルズ株式会社 | 化学機械研磨用組成物 |
| MX2011006313A (es) * | 2008-12-15 | 2011-09-27 | Zealand Pharma As | Analogos de glucagon. |
| US9156901B2 (en) * | 2009-07-13 | 2015-10-13 | Ditte Riber | Acylated glucagon analogues |
| CN102286092B (zh) * | 2011-09-14 | 2014-01-01 | 深圳翰宇药业股份有限公司 | 利拉鲁肽的固相合成方法 |
| EA201490982A1 (ru) * | 2011-12-23 | 2015-01-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
-
2012
- 2012-05-15 EP EP12168119.1A patent/EP2664374A1/en not_active Ceased
-
2013
- 2013-05-13 JP JP2015512007A patent/JP6162795B2/ja active Active
- 2013-05-13 SI SI201331208T patent/SI3127604T1/sl unknown
- 2013-05-13 SI SI201330739T patent/SI2849882T1/sl unknown
- 2013-05-13 CN CN201380024470.5A patent/CN104271227B/zh active Active
- 2013-05-13 EP EP13722408.5A patent/EP2849882B1/en active Active
- 2013-05-13 AU AU2013261894A patent/AU2013261894B2/en active Active
- 2013-05-13 CA CA3096624A patent/CA3096624C/en active Active
- 2013-05-13 KR KR1020197014335A patent/KR102094928B1/ko active Active
- 2013-05-13 MX MX2017006522A patent/MX363728B/es unknown
- 2013-05-13 RU RU2014148530A patent/RU2640812C2/ru active
- 2013-05-13 PL PL16179885T patent/PL3127604T3/pl unknown
- 2013-05-13 WO PCT/EP2013/059759 patent/WO2013171135A1/en not_active Ceased
- 2013-05-13 SG SG11201406888QA patent/SG11201406888QA/en unknown
- 2013-05-13 CA CA2868144A patent/CA2868144C/en active Active
- 2013-05-13 MY MYPI2018000443A patent/MY184184A/en unknown
- 2013-05-13 KR KR1020147031824A patent/KR102018160B1/ko active Active
- 2013-05-13 ES ES16179885.5T patent/ES2692364T3/es active Active
- 2013-05-13 MX MX2014013505A patent/MX349822B/es active IP Right Grant
- 2013-05-13 MY MYPI2014703386A patent/MY172395A/en unknown
- 2013-05-13 EP EP16179885.5A patent/EP3127604B1/en active Active
- 2013-05-13 PL PL13722408T patent/PL2849882T3/pl unknown
- 2013-05-13 BR BR112014028334-6A patent/BR112014028334B1/pt active IP Right Grant
- 2013-05-13 NZ NZ631215A patent/NZ631215A/en unknown
- 2013-05-13 ES ES13722408.5T patent/ES2637415T3/es active Active
- 2013-05-13 HR HRP20171058TT patent/HRP20171058T1/hr unknown
- 2013-05-14 AR ARP130101662A patent/AR091044A1/es active IP Right Grant
-
2014
- 2014-10-16 ZA ZA2014/07528A patent/ZA201407528B/en unknown
- 2014-10-30 IL IL235425A patent/IL235425B/en active IP Right Grant
- 2014-11-12 US US14/539,126 patent/US9522874B2/en active Active
-
2016
- 2016-11-10 US US15/348,093 patent/US9802886B2/en active Active
-
2017
- 2017-10-11 US US15/730,585 patent/US20180029978A1/en not_active Abandoned
-
2018
- 2018-10-17 HR HRP20181696TT patent/HRP20181696T1/hr unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006233405A (ja) * | 2005-08-16 | 2006-09-07 | Asahi Kasei Chemicals Corp | 繊維処理剤 |
| CN101993395A (zh) * | 2009-08-11 | 2011-03-30 | 住友化学株式会社 | 化合物和含有该化合物的光致抗蚀剂组合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104271227B (zh) | 赖氨酸‑谷氨酸二肽衍生物 | |
| KR101467598B1 (ko) | Ｈｃｖ 프로테아제 억제제 중간체의 제조방법 | |
| CN110964085B (zh) | 一种卡非佐米及其衍生物的制备方法 | |
| HUE027735T2 (en) | A process for the preparation of process intermediates for the synthesis of argatroban monohydrate | |
| CN102329376B (zh) | 环(苯丙氨酰-n-甲基亮氨酰-亮氨酰-n-甲基亮氨酰-亮氨酰)及其合成方法与应用 | |
| CN114667136A (zh) | Trofinetide的组合物 | |
| EP3986400B1 (en) | Processes and intermediates for producing diazaspiro lactam compounds | |
| JPH08301831A (ja) | スチルベン誘導体及びそれを含有する制癌剤 | |
| HK1200753B (en) | Lysin-glutamic acid dipeptide derivatives | |
| RU2741389C1 (ru) | Способ получения промежуточного соединения для синтеза лекарственного средства | |
| HK40120549A (en) | Processes and intermediates for producing diazaspiro lactam compounds | |
| CN118255707A (zh) | 一种加巴喷丁恩那卡比有关物质的制备方法 | |
| JP2608345B2 (ja) | ペプチドの溶解および反応媒質、これを使用するペプチドの合成方法 | |
| WO2019066578A1 (ko) | 의약품 합성용 중간체 화합물의 제조 방법 | |
| WO2014102816A1 (en) | Process for preparation of telaprevir and intermediates | |
| WO2017145028A1 (en) | Process for preparation of ledipasvir |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1200753 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1200753 Country of ref document: HK |
|
| IP01 | Partial invalidation of patent right |
Commission number: 4W110948 Conclusion of examination: Maintain the validity of the patent on the basis of the revised text submitted by the patentee on October 23, 2020 Decision date of declaring invalidation: 20210114 Decision number of declaring invalidation: 47590 Denomination of invention: Lysine glutamic acid dipeptide derivative Granted publication date: 20161228 Patentee: Hoffman-La Roche Ltd. |
|
| IP01 | Partial invalidation of patent right |